Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Proceedings of the National Academy of Sciences of the United States of America|August 6, 1996
Sin3 corepressor function in Myc-induced transcription and transformationS E Harper, Y Qiu, P A Sharp
The Journal of Experimental Medicine|September 1, 1987
Regulation of autoimmunity and donor cell engraftment by recipient Lyt-2+ cells during the graft-versus-host reactionS E Harper, J R Roubinian, W E Seaman
The Journal of Parasitology|October 7, 2017
Development and Characterization of 12 Novel Polymorphic Microsatellite Loci for the Mammal Chewing Louse Geomydoecus aurei (Insecta: Phthiraptera) and a Comparison of Next-Generation Sequencing Approaches for Use in ParasitologyJ E Light, S E Harper, K P Johnson, et al.
Medgenmed : Medscape General Medicine|April 20, 2002
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDsD J Watson, S E Harper, P L Zhao, et al.
Clinical Therapeutics|August 25, 2001
Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritisJ M Pellissier, W L Straus, D J Watson, et al.
Alimentary Pharmacology & Therapeutics|September 21, 2001
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trialsC J Hawkey, L Laine, S E Harper, et al.
Alimentary Pharmacology & Therapeutics|January 3, 2001
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humansC J Hawkey, L Jackson, S E Harper, et al.
Archives of Internal Medicine|October 21, 2000
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritisD J Watson, S E Harper, P L Zhao, et al.
The Medical Journal of Australia|August 19, 1999
Transmission of hepatitis C within Australian prisonsP S Haber, S J Parsons, S E Harper, et al.
Alimentary Pharmacology & Therapeutics|June 26, 1999
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofenF L Lanza, M F Rack, T J Simon, et al.
Pageof 2